Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

330
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

256
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Autoimmune Disorders01:29

Autoimmune Disorders

2.2K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.2K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

373
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
373
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

704
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
704

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How Real Is Seronegative Autoimmune Hepatitis?

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Regulatory T-cells in autoimmune hepatitis: An historical perspective with hints to the future.

JHEP reports : innovation in hepatology·2026
Same author

The Geoepidemiology of Autoimmune Hepatitis.

Clinical reviews in allergy & immunology·2026
Same author

Clinical course and prognostic risk factors of SARS-CoV-2 vaccine-related hepatitis: differentiating severe acute respiratory syndrome coronavirus 2 vaccine-associated liver injury from autoimmune hepatitis.

European journal of gastroenterology & hepatology·2026
Same author

Can we cure autoimmune hepatitis?

Current opinion in immunology·2025
Same author

HLA alleles predisposing to autoimmunity are linked to impaired immunoregulation in patients with juvenile autoimmune liver disease and in their first-degree relatives.

Journal of autoimmunity·2025

Related Experiment Video

Updated: Mar 29, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.5K

Paediatric Autoimmune Liver Disease.

Rodrigo Liberal, Diego Vergani, Giorgina Mieli-Vergani

    Digestive Diseases (Basel, Switzerland)
    |December 8, 2015
    PubMed
    Summary

    Childhood autoimmune liver diseases (AILD), including autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (ASC), require prompt immunosuppressive treatment. Early intervention improves outcomes, but ASC may have a worse long-term prognosis due to ongoing bile duct disease.

    Area of Science:

    • Pediatric Gastroenterology and Hepatology
    • Immunology
    • Autoimmune Liver Diseases

    Background:

    • Childhood autoimmune liver diseases (AILD), specifically autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (ASC), present non-specifically.
    • AIH and ASC are autoimmune-driven liver disorders with distinct clinical and immunological features.

    Purpose of the Study:

    • To review the presentation, treatment, and pathogenesis of pediatric AIH and ASC.
    • To highlight the importance of early immunosuppressive therapy and discuss emerging treatment strategies.

    Main Methods:

    • Literature review of pediatric autoimmune liver diseases.
    • Analysis of treatment responses and pathogenic mechanisms.

    Main Results:

    More Related Videos

    Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
    05:56

    Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

    Published on: August 29, 2025

    683
    The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
    09:03

    The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

    Published on: February 3, 2012

    20.0K

    Related Experiment Videos

    Last Updated: Mar 29, 2026

    Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
    11:36

    Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

    Published on: May 29, 2020

    3.5K
    Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
    05:56

    Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

    Published on: August 29, 2025

    683
    The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
    09:03

    The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

    Published on: February 3, 2012

    20.0K
    • AIH responds well to immunosuppression; refractory cases may benefit from mycophenolate mofetil or calcineurin inhibitors.
    • ASC also responds to immunosuppression if initiated early, but bile duct progression affects long-term prognosis in about 50% of patients.
    • Th17 immune responses are implicated in ASC's bile duct damage, potentially linked to intestinal inflammation.

    Conclusions:

    • Prompt immunosuppressive treatment is crucial for managing pediatric AIH and ASC.
    • Understanding the pathogenesis, including immune responses and genetic factors, is key to developing novel therapies for AILD.
    • Liver transplantation remains an option for end-stage liver disease or fulminant failure.